Literature DB >> 28488220

PLA2R-positive (primary) membranous nephropathy in a child with IPEX syndrome.

Teresa Chuva1, Frederick Pfister2, Ortraud Beringer3, Kerstin Felgentreff3, Maike Büttner-Herold2, Kerstin Amann2.   

Abstract

BACKGROUND: Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare primary immunodeficiency syndrome characterized by the development of multiple autoimmune disorders in affected individuals. Different forms of renal injury have been reported in IPEX syndrome, and membranous nephropathy (MN) is among the most common glomerulopathies found. However, the exact pathogenesis of MN in this setting has not been elucidated, and it is not clear whether it is part of the clinical spectrum of the disease or secondary to medications, infections or other concomitant insults. DIAGNOSIS/TREATMENT: We describe a child diagnosed with IPEX syndrome shortly after birth who presented with nephrotic syndrome at the age of 11 weeks. Renal biopsy revealed a MN with enhanced immunohistochemical staining for phospholipase A2 receptor (PLA2R).
CONCLUSION: This is the first report of a PLA2R-positive MN in a patient with IPEX syndrome. We suggest that, in this context, MN results from an autoimmune process against podocytic antigens, namely PLA2R.

Entities:  

Keywords:  Autoimmunity; IPEX syndrome; Membranous nephropathy; Phospholipase A2 receptor

Mesh:

Substances:

Year:  2017        PMID: 28488220     DOI: 10.1007/s00467-017-3682-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  15 in total

Review 1.  Regulatory T cells in the control of immune pathology.

Authors:  K J Maloy; F Powrie
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

Review 2.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 3.  Pathogenesis of membranous nephropathy: recent advances and future challenges.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

4.  The spectrum of autoantibodies in IPEX syndrome is broad and includes anti-mitochondrial autoantibodies.

Authors:  Masanobu Tsuda; Troy R Torgerson; Carlo Selmi; Eleonora Gambineri; Magda Carneiro-Sampaio; Sara Ciullini Mannurita; Patrick S C Leung; Gary L Norman; M Eric Gershwin
Journal:  J Autoimmun       Date:  2010-07-22       Impact factor: 7.094

5.  IPEX and the role of Foxp3 in the development and function of human Tregs.

Authors:  Séverine Le Bras; Raif S Geha
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

6.  Familial IPEX syndrome: different glomerulopathy in two siblings.

Authors:  Eujin Park; Hye Jin Chang; Jae Il Shin; Beom Jin Lim; Hyeon Joo Jeong; Kyoung Bun Lee; Kyoung Chul Moon; Hee Gyung Kang; Il-Soo Ha; Hae Il Cheong
Journal:  Pediatr Int       Date:  2015-02-24       Impact factor: 1.524

7.  Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy.

Authors:  Elion Hoxha; Ursula Kneißler; Gesa Stege; Gunther Zahner; Ina Thiele; Ulf Panzer; Sigrid Harendza; Udo M Helmchen; Rolf A K Stahl
Journal:  Kidney Int       Date:  2012-06-06       Impact factor: 10.612

8.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

9.  Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy.

Authors:  Durga Kanigicherla; Jennet Gummadova; Edward A McKenzie; Stephen A Roberts; Shelley Harris; Milind Nikam; Kay Poulton; Lorna McWilliam; Colin D Short; Michael Venning; Paul E Brenchley
Journal:  Kidney Int       Date:  2013-01-30       Impact factor: 10.612

10.  Renal involvement in the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) disorder.

Authors:  Yuri Sheikine; Craig B Woda; Pui Y Lee; Talal A Chatila; Sevgi Keles; Louis-Marie Charbonnier; Birgitta Schmidt; Seymour Rosen; Nancy M Rodig
Journal:  Pediatr Nephrol       Date:  2015-04-25       Impact factor: 3.714

View more
  6 in total

Review 1.  A novel FOXP3 mutation in a Chinese child with IPEX-associated membranous nephropathy.

Authors:  Liwen Tan; Yunfei An; Qin Yang; Haiping Yang; Gaofu Zhang; Qiu Li; Mo Wang
Journal:  Mol Genet Genomic Med       Date:  2022-04-18       Impact factor: 2.473

2.  A delayed diagnosis of atypical immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: A case report.

Authors:  Ying Zhang; Hanmin Liu; Tao Ai; Wanmin Xia; Tingting Chen; Lei Zhang; Xiulan Luo; Yaping Duan
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

3.  Clinicopathologic features of non-lupus membranous nephropathy in a pediatric population.

Authors:  Paul Miller; Li Lei; Vivek Charu; John Higgins; Megan Troxell; Neeraja Kambham
Journal:  Pediatr Nephrol       Date:  2022-03-25       Impact factor: 3.651

Review 4.  How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy.

Authors:  Tiffany N Caza; Laith F Al-Rabadi; Laurence H Beck
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

5.  Renal Involvement in IPEX Syndrome With a Novel Mutation of FOXP3: A Case Report.

Authors:  Ruijuan Ke; Ying Zhu; Fang Deng; Daliang Xu
Journal:  Front Genet       Date:  2022-02-02       Impact factor: 4.599

6.  Non-lupus full-house nephropathy-immune dysregulation as a rare cause of pediatric nephrotic syndrome: Answers.

Authors:  Orsolya Horváth; György S Reusz; Veronika Goda; Kata Kelen; István Balogh; Magdolna Kardos; Krisztián Kállay; Áron Cseh; Attila J Szabó; Gergely Kriván
Journal:  Pediatr Nephrol       Date:  2021-12-17       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.